Last Updated:

TG Therapeutics

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.



Burn Rate (Quarterly)


Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Ublituximab + Ibrutinib | GENUINE

R/R High Risk CLL

Phase 3


Umbra +/- Ublitux +/- Benda (UNITY-NHL)


Phase 3


Umbra + Ublitux (UNITY-CLL)

Frontline & R/R CLL

Phase 3 (Regulatory Submission & Full Data Presentation)

Year-end 2020

Ublituximab (ULTIMATE 1 & 2)

Multiple Sclerosis

Phase 3 (Top-line Data)

H2 2020

TG-1101 and TG-1202 (UNITY)

Chronic Lymphocytic Leukemia (CLL) (FL & R/R)

Phase 3 (Regulatory Submission)

Year-end 2020

Umbralisib Monotherapy (UNITY-NHL)


Data Presentation

Q4 2020

Umbra + Ublitux + Vene (ULTRA-V)

CLL (chronic lymphocytic leukemia)

Phase 2


TG-1701 (BTK Inhibitor)

B-Cell Malignancies

Phase 1




Phase 1



BET Inhibitor



Recent Posts

See What The Community Is Saying - Click To See Full Post

TGTX - TG Therapeutics Provide...

#TGTX "announced its financial results for the third quarter endedSeptember 30, 2020and recent company developments. Recent Developments and Highlights ASH 2020 Presentations:
• Four abstracts have b...

Will TGTX's Unity CLL PFS Read...

QUESTION: Is TGTX going to report positive results that increases their stock price, when they report their upcoming Phase 3 Unity-CLL PFS readout*? On Sept. 25, 2018, TGTX took a big hit to its cred...

TGTX - Announces Fast Track De...

#TGTX "announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the combination of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclon...

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

#TGTX - Acceptance of #NDA for...

#TGTX announced that the FDA has accepted their NDA #umbralisib. See more at our AmpCard for more details. #TGTX, #Umbralisib, #MZL, #FL, #lymphoma...

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon